Over $600 billion in European goods were imported by the U.S. last year. New tariffs from President Trump will likely hit ...

Novo Nordisk's sales and profits were both up around 30% last quarter. Its GLP-1 weight loss drug has been a driving force ...

Hims & Hers Health (HIMS) stock hit a new all-time high on Thursday as retail investors have taken interest in the telehealth ...

The data, published in JAMA Psychiatry, add to the growing body of evidence supporting the use of GLP-1 receptor agonists for ...

Isomorphic Labs, a spin-off from DeepMind, is applying AI-first principles to drug discovery rather than just protein ...

The next FDA Commissioner could solve two big problems with one powerful policy: encourage independent testing of both ...

Eli Lilly and Company’s LLY shares have risen 4.3% since it reported fourth-quarter results on Feb. 6. Lilly’s fourth-quarter ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

While first-generation glucagon-like peptide-1 receptor agonists have clearly taken the obesity market by storm, generating billions of dollars for Novo Nordisk A/S and Eli Lilly and Co., several ...

Conagra adds an ‘On Track’ badge on packaging for 26 of its Healthy Choice frozen meals that call out GLP-1 ...

The “Check Before You Inject” ad goes on to note that some vials of compounded semaglutide “have been found to contain ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...